Novel Strategies for Reducing Burn Scar Itch

Launched by THE UNIVERSITY OF TEXAS MEDICAL BRANCH, GALVESTON · Jan 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to help people with itchy burn scars feel more comfortable. Researchers want to see if a combination of three medications—diphenhydramine (commonly known as Benadryl), famotidine (Pepcid), and cromolyn sodium—can reduce the itchiness caused by burn scars. The study will include adults aged 18 to 79 who have itchy burn scars, and participation will require consent and the ability to follow the study procedures.

If you or someone you know is interested in joining, participants should be willing to adhere to the study guidelines and return for follow-up assessments. However, those with certain medical conditions, other ongoing clinical trials, or specific medication use may not be eligible. This trial is not yet recruiting participants, but it aims to improve the quality of life for individuals dealing with the discomfort of burn scar itch.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must meet all the inclusion criteria in order to be eligible to participate in the study.
• • Participant has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.
• • Adults: ≥18 to \<80 years of age.
• • Has an itchy burn scar.
• Exclusion Criteria:
• • Participants meeting any of the exclusion criteria at baseline will be excluded from study participation.
• • Failure to obtain consent or unable to return for follow up assessments.
• • Patient is unable to follow the protocol required assessments.
• • Member of a vulnerable class (e.g., prisoners, pregnant participant, etc.).
• • Any medical condition that, in the opinion of the investigator or physician, would place the participant at increased risk for participation.
• • Concurrent participation in another interventional clinical trial (to avoid confounding factors that may influence outcomes).
• • History of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the participant to comply with the study procedures or follow the investigators instructions.
• • Age \< 18 or ≥ 80 years.
• • Taking one of the following medications: cefuroxime, dasatinib, delavirdine, neratinib, pazopanib, risedronate, or tizanidine.
• • Has a pre-existing inflammatory or itchy skin disease.
• • Is taking an H2 antihistamine for another indication.